SEMHF:OTC-Siemens Healthineers AG (USD)

COMMON STOCK | Diagnostics & Research | OTC

Last Closing Price

USD 68.95

Change

0.00 (0.00)%

Market Cap

USD 77.80B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers; and robotic-assisted platform for endo-vascular coronary and peripheral vascular interventions. This segment's principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. In addition, the company offers equipment performance management, clinical education and e-learning, asset management, and managed departmental services, as well as digital health products and services. Siemens Healthineers collaborates with HERE Technologies. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG is a subsidiary of Siemens Aktiengesellschaft.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-20 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SMMNY Siemens Healthineers AG

-0.11 (-0.32%)

USD77.80B 37.07 22.57
LZAGF Lonza Group Ltd

+5.05 (+0.63%)

USD60.31B 78.23 96.02
LZAGY Lonza Group Ltd

-1.04 (-1.28%)

USD60.31B 78.87 96.02
RYLPF Koninklijke Philips N.V

+0.45 (+0.97%)

USD42.96B 32.20 17.51
SSMXF Sysmex Corporation

-1.85 (-1.36%)

USD28.50B 81.26 0.34
SSMXY Sysmex Corporation

-0.73 (-1.07%)

USD28.44B 81.07 0.34
ERFSF Eurofins Scientific SE

-2.53 (-1.70%)

USD28.35B 30.70 16.49
BMXMF bioMérieux S.A

-2.50 (-1.87%)

USD15.94B 26.61 17.78
DSRLF DiaSorin S.p.A

-38.29 (-16.07%)

USD13.05B 37.74 30.77
RTNXF Renalytix Plc

-5.73 (-38.85%)

USD1.07B N/A N/A

ETFs Containing SEMHF

Symbol Name Weight Mer Price(Change) Market Cap
FPXI First Trust International.. 0.00 % 0.70 %

-1.94 (-2.86%)

USD1.26B
XDGM:F Xtrackers (IE) Public Lim.. 0.00 % 0.40 %

-0.96 (-3.02%)

USD0.11B
XDGM:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.40 %

-0.58 (-1.84%)

USD0.11B
IQQM:XETRA iShares Public Limited Co.. 0.00 % 0.40 %

-1.43 (-2.01%)

USD0.58B
F751:XETRA ComStage Alpha Deutschlan.. 0.00 % 0.69 %

N/A

USD0.01B
EXSD:XETRA iShares STOXX Europe Mid .. 0.00 % 0.20 %

-1.20 (-2.12%)

USD5,934.00B
EXS3:XETRA iShares MDAX UCITS ETF (D.. 0.00 % 0.51 %

-4.85 (-1.64%)

USD5,933.92B
EXS2:XETRA iShares TecDAX UCITS ETF .. 0.00 % 0.51 %

-0.56 (-1.59%)

USD5,933.97B
ELF1:XETRA Deka MDAX UCITS ETF 0.00 % 0.00 %

-5.60 (-1.66%)

USD0.44B
E908:XETRA Lyxor 1 - TecDAX UCITS ET.. 0.00 % 0.40 %

-0.56 (-1.84%)

USD0.10B
E907:XETRA Lyxor 1 - MDAX UCITS ETF 0.00 % 0.30 %

-3.08 (-1.65%)

USD0.21B
C007:XETRA Lyxor MDAX® (DR) UCITS E.. 0.00 % 0.30 %

-0.51 (-1.62%)

USD0.27B
IQQM:F iShares Public Limited Co.. 0.00 % 0.40 %

-1.31 (-1.85%)

USD0.58B
FPXE First Trust IPOX Europe E.. 0.00 % 0.70 %

-0.81 (-2.46%)

USD6.00M
F751:F ComStage Alpha Deutschlan.. 0.00 % 0.69 %

N/A

USD0.01B
EXS3:F iShares MDAX UCITS ETF (D.. 0.00 % 0.51 %

-5.45 (-1.84%)

USD5,933.92B
EXS2:F iShares TecDAX UCITS ETF .. 0.00 % 0.51 %

-0.79 (-2.25%)

USD5,933.97B
ELF1:F Deka MDAX UCITS ETF 0.00 % 0.00 %

-6.05 (-1.80%)

USD0.44B
E908:F Lyxor 1 - TecDAX UCITS ET.. 0.00 % 0.40 %

-1.06 (-3.47%)

USD0.10B
E907:F Lyxor 1 - MDAX UCITS ETF 0.00 % 0.30 %

-6.06 (-3.21%)

USD0.21B
C007:F Lyxor MDAX® (DR) UCITS E.. 0.00 % 0.30 %

-0.75 (-2.37%)

USD0.27B
XDGM:LSE Xtrackers (IE) Plc - Xtra.. 0.00 % 0.40 %

-0.58 (-1.84%)

USD0.10B
XUKS:LSE Xtrackers - FTSE 100 Shor.. 0.00 % 0.50 %

+2.20 (+0.66%)

USD0.01B
DJMC:LSE iShares Public Limited Co.. 0.00 % 0.40 %

-106.87 (-1.75%)

USD0.58B
DEAM:XETRA Invesco Markets II PLC - .. 0.00 % 0.19 %

-1.01 (-1.70%)

USD0.30B

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 34.67% 73% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.67% 71% C- 69% D+
Trailing 12 Months  
Capital Gain 52.22% 66% D 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 52.22% 66% D 65% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.94% 29% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.94% 29% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 15.61% 100% A+ 88% B+
Risk Adjusted Return 70.04% 85% B 89% B+
Market Capitalization 77.80B 98% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 37.15 35% F 19% F
Price/Book Ratio 4.30 68% D+ 28% F
Price / Cash Flow Ratio 40.35 12% F 6% F
EV/EBITDA 22.57 35% F 17% F
Management Effectiveness  
Return on Equity 13.67% 79% C+ 76% C
Return on Invested Capital 12.56% 65% D 77% C+
Return on Assets 4.81% 81% B- 80% B-
Debt to Equity Ratio 0.39% 53% F 79% C+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.43 60% D- 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector